Investment Column: Chemring defensive in dangerous times

Alkane Energy; Alliance Pharma


Our view: Buy

Share price: 2160p (+170p)

We don't always get it right, but those of you who followed our advice towards the end of last year, when we first suggested buying Chemring shares at 1613p, can certainly afford a cheer.

The stars still seem aligned for the defence group, which makes consumable counter-measures and "energetics", such as flares. The public sector is its biggest client in a host of different countries, and it makes 60 per cent of its revenues in dollars and euros.

According to Chemring's brokers at Investec, turnover will reach £470m this year, up from £350m in 2008. The group's orders are up 39 per cent.

Yes, the stock has appreciated at a terrific rate in the past few months but, according to analysts at RBS, it is still worth buying. "The shares are currently trading on a October 2009 price earnings ratio of 10.1 times, and enterprise value to Ebitda of 6.7 times," they say. "This is still a significant discount to [a] number of larger, but in our view, lower quality peers in the FTSE 350 aerospace and defence sector[s]."

The shares are about as defensive as you get in these markets and, while we would not advise sitting on the stock indefinitely, if investors think the downturn will last for the foreseeable future, Chemring shares are worth keeping hold of.

Barring anything unexpected, and there was no sign of anything untoward yesterday's trading update, the shares will have a bumper 2009. Buy.

Alkane Energy

Our view: Buy

Share price: 16.5p (+1.75p)

You have to take your hat off to Alkane Energy. For good reason, and despite the misery for some companies in the continuing recession, it is upbeat about the future and says it is having no trouble in attracting investors, at least to meetings.

The Aim-listed company specialises in building and operating methane extraction plants, largely at disused mines in the Midlands. Alkane says the energy is clean and, with stellar full-year numbers announced yesterday, no debts and the price of its energy fixed for another year, the group is confident that its investors will benefit from holding the stock.

Neil O'Brien, Alkane's new chief executive, says he is excited about the future and that for the first time since the collapse of Lehman Brothers, he has filled up his diary for the next few days with meetings in the City – a sure sign that confidence is returning, albeit gradually. Whether this is the case is in our view questionable, but that does not detract from the fact that investors are prepared to listen to solid small caps with a good story. Alkane will start more projects this year, and the resultant power will not be locked in at current market levels, allowing the group to take advantage of higher energy prices in the coming year, Mr O'Brien says. A new site costs an average of £2.5m, and Alkane says it has enough cash in the bank to cover at least three projects this year.

There are clearly compelling reasons to buy Alkane shares. The big white elephant in the room, lest investors forget it, is that as a small-cap company, Alkane will suffer disproportionately with any slight change in sentiment. The shares rose 11.7 per cent yesterday and experts at house broker Brewin Dolphin predictably say the stock is a buy with a 24p price target. We would tentatively agree that they will rise. Buy.

Alliance Pharma

Our view: Hold

Share price: 8.25p (+1.1p)

To a casual observer, Alliance Pharma may not look too different to how it did two years ago. The chief executive, John Dawson, would disagree, saying that the group's marketing strategy has changed and, with a new venture capital investor, MVM, on board, the need for cash from outside to fund all-important acquisitions, has gone. The difference, Mr Dawson would argue, is reflected in its share price – up 75 per cent since December.

The group specialises in buying established, off-patent drugs that do not make enough money to attract generics firms. Yesterday, it published its full-year results, saying its pre-tax profits were £2.4m – up from a loss of £3.2m last year. Most significantly for investors, the group said it expects to start paying a dividend within the next 12 months. Despite the shares trading 15.8 per cent higher, analysts at house broker Numis reckon the stock is still undervalued. They said the shares were worth 11p, based on an average of sector peers' enterprise value to Ebitda.

While acknowledging that the shares have performed well in recent months, we see few catalysts from here. We would wait for some softening in the share price before buying. Hold.

Suggested Topics
PROMOTED VIDEO
News
ebooksAn unforgettable anthology of contemporary reportage
Life and Style
tech

Board creates magnetic field to achieve lift

News
There have been various incidents of social media users inadvertently flouting the law
news

Life and Style
Stack ‘em high?: quantity doesn’t always trump quality, as Friends of the Earth can testify
techThe proliferation of online petitions allows us to register our protests at the touch of a button. But do they change anything?
News
Bourgogne wine maker Laboure-Roi vice president Thibault Garin (L) offers the company's 2013 Beaujolais Nouveau wine to the guest in the wine spa at the Hakone Yunessun spa resort facilities in Hakone town, Kanagawa prefecture, some 100-kilometre west of Tokyo
i100
Sport
CSKA Moscow celebrate after equalising with a late penalty
footballCSKA Moscow 2 Manchester City 2: Premier League champions let two goal lead slip in Russia
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Trainee Recruitment Consultants

£20000 - £25000 per annum + OTE £Competitive: SThree: SThree Group and have be...

Helpdesk Analyst

£23000 per annum + pension and 22 days holiday: Ashdown Group: An established ...

Senior Helpdesk Analyst / Service Desk Co-ordinator

£27000 per annum + pension, 22 days holiday: Ashdown Group: An established ind...

Senior Pensions Administrator

£23000 - £26000 Per Annum: Clearwater People Solutions Ltd: Our client is curr...

Day In a Page

Indiana serial killer? Man arrested for murdering teenage prostitute confesses to six other murders - and police fear there could be many more

A new American serial killer?

Police fear man arrested for murder of teen prostitute could be responsible for killing spree dating back 20 years
Sweetie, the fake 10-year-old girl designed to catch online predators, claims her first scalp

Sting to trap paedophiles may not carry weight in UK courts

Computer image of ‘Sweetie’ represented entrapment, experts say
Fukushima nuclear crisis: Evacuees still stuck in cramped emergency housing three years on - and may never return home

Return to Fukushima – a land they will never call home again

Evacuees still stuck in cramped emergency housing three years on from nuclear disaster
Wildlife Photographer of the Year: Intimate image of resting lions claims top prize

Wildlife Photographer of the Year

Intimate image of resting lions claims top prize
Online petitions: Sign here to change the world

Want to change the world? Just sign here

The proliferation of online petitions allows us to register our protests at the touch of a button. But do they change anything?
Ed Sheeran hits back after being labelled too boring to headline festivals

'You need me, I don’t need you'

Ed Sheeran hits back after being labelled too boring to headline festivals
How to Get Away with Murder: Shonda Rhimes reinvents the legal drama

How to Get Away with Murder

Shonda Rhimes reinvents the legal drama
A cup of tea is every worker's right

Hard to swallow

Three hospitals in Leicester have banned their staff from drinking tea and coffee in public areas. Christopher Hirst explains why he thinks that a cuppa is every worker's right
Which animals are nearly extinct?

Which animals are nearly extinct?

Conservationists in Kenya are in mourning after the death of a white northern rhino, which has left the species with a single male. These are the other species on the brink
12 best children's shoes

Perfect for leaf-kicking: 12 best children's shoes

Find footwear perfect to keep kids' feet protected this autumn
Anderlecht vs Arsenal: Gunners' ray of light Aaron Ramsey shines again

Arsenal’s ray of light ready to shine again

Aaron Ramsey’s injury record has prompted a club investigation. For now, the midfielder is just happy to be fit to face Anderlecht in the Champions League
Comment: David Moyes' show of sensitivity thrown back in his face by former Manchester United manager Sir Alex Ferguson

Moyes’ show of sensitivity thrown back in his face... by Ferguson

Manchester United legend tramples on successor who resisted criticising his inheritance
Two super-sized ships have cruised into British waters, but how big can these behemoths get?

Super-sized ships: How big can they get?

Two of the largest vessels in the world cruised into UK waters last week
British doctors on brink of 'cure' for paralysis with spinal cord treatment

British doctors on brink of cure for paralysis

Sufferers can now be offered the possibility of cure thanks to a revolutionary implant of regenerative cells
Ranked seventh in world’s best tourist cities - not London, or Edinburgh, but Salisbury

Lonely Planet’s Best in Travel 2015

UK city beats Vienna, Paris and New York to be ranked seventh in world’s best tourist destinations - but it's not London